糖皮质激素治疗系统性红斑狼疮的研究进展  

Research progress of Glucocorticoids in the treatment of systemic lupus erythematosus

作　　者：杨晓璇 朱洪涛[1] ANG Xiaoxuan;ZHU Hongtao(Third Department of Pediatrics,Pediatric Center,the First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830000,China)

机构地区：[1]新疆医科大学第一附属医院儿科中心儿内三科,新疆乌鲁木齐830000

出　　处：《医药前沿》2025年第7期26-31,共6页Journal of Frontiers of Medicine

摘　　要：糖皮质激素(GCs)是治疗系统性红斑狼疮(SLE)的基础用药,能显著改善SLE患者的预后。然而,GCs在临床应用中面临诸多挑战,部分患者可能出现依赖性或耐药性,且长期使用可能导致严重不良反应。近年来,随着对GCs临床应用难题的深入研究,SLE治疗中GCs的使用观念和策略正在发生转变。本文综述GCs治疗SLE的研究进展,以期为SLE患者临床个体化用药提供思路。Glucocorticoids(GCs)are the basic drugs for the treatment of systemic lupus erythematosus(SLE),which can significantly improve the prognosis of SLE patients.However,GCs also face many challenges in clinical application.Some patients may have dependence or drug resistance,and long-term use may lead to serious adverse reactions.In recent years,with the in-depth study of the clinical application problems of GCs,the use concepts and strategies of GCs in SLE treatment are changing.This article reviews the research progress of GCs in the treatment of SLE,in order to provide ideas for clinical individualized medication of patients with SLE.

关 键 词：系统性红斑狼疮 糖皮质激素 作用机制 不良反应 个体化用药 综述 

分 类 号：R593[医药卫生—内科学]